Adrenocortical carcinoma (ACC) is a malignant endocrine tumour. The rarity of the disease has stymied therapeutic development. Age distribution shows two peaks: the first and fifth decades of life, with children and women more frequently affected. Although 60-70% of ACCs are biochemically found to overproduce hormones, it is not clinically apparent in many cases. If present, endocrine symptoms include signs of hypercortisolaemia, virilisation or gynaecomastia. ACC carries a poor prognosis, and a cure can be achieved only by complete surgical resection. Mitotane is used both as an adjuvant treatment and also in non-operative patients. The role of radio-and chemotherapy is still controversial. The post-operative disease free survival is low and oscillates around 30% due to high tumour recurrence rate. The diagnosis is based on tumour histological assessment with the use of the Weiss score, however urinary steroid profiling (if available) can serve to differentiate between ACC and other adrenal tumours. Conventional prognostic markers in ACC include stage and grade of disease, and, as currently reported, the presence of hypercortisolaemia. Molecular analysis has had a significant impact on the understanding of the pathogenetic mechanism of ACC development and the evaluation of prognostic and predictive markers, among which alterations of the IGF system, the Wnt pathway, p53 and molecules involved in cancer cell invasion properties and angiogenesis seem to be very promising. We here summarise our own experience related to the management of ACC and present a literature overview. We have not aimed to include a detailed summary of the molecular alterations biology described in ACC, as this has already been addressed in other papers. 
Introduction
Adrenocortical carcinoma (ACC) has a reported incidence of 0.5-2 cases per million per year [1, 2] and affects women more frequently than men (female to male ratio is about 2.5-3:1) [3] . Hormonally active tumours are also more common in women than in men. Age distribution shows two peaks, in the first and fifth decades of life [1, 2, 4] . In the last two decades, significant progress has been made in the understanding of the molecular biology of ACC, although this has resulted only in a small improvement in patient survival. The Wnt/β-catenin
Pathogenesis and molecular features
Adrenocortical tumours (ACTs) occur as a component of several hereditary tumour syndromes, which include Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, multiple endocrine neoplasia 1, Carney complex, and congenital adrenal hyperplasia. The genes involved in these syndromes have also been shown to play a role in the pathogenesis of sporadic ACTs. ACC may also be either of sporadic or familiar origin. Familiar syndromes include: Li-Fraumeni syndrome (LFS) (TP53 mutation), Beckwith-Wiedemann syndrome (11p15 defect in genomic imprinting), Gardner syndrome (several changes in 5q21, APC gene, and Wnt Pathway), Multiple Endocrine Neoplasia type 1 (MEN1), MEN 2, McCune-Albright syndrome (GNAS1 gene mutation), and Carney complex (CNC) [6] [7] [8] [9] . Germline mutations of the p53 are present in about 4% of patients with ACC and in 70% of patients with LFS [10] . Other important genes involved in the pathogenesis of ACC include: CTNNB1 gene (β-catenin) (3p21), PRKARIA (17q23-q24), Ras genes, TP53(17p13), GNAS(20q13), and MEN1(11q13) [11] . The two most frequent alterations observed in ACC to date are overexpression of IGF-2 and constitutive activation of the Wnt/β-catenin pathway [5] . IGF-2 gene is located at 11p15 and regulates growth and apoptosis through an interaction with the IGF-1 receptor. The interaction of IGF-2 with the IGF-1 receptor activates two pathways involved in carcinogenesis (PI-3/AKT/mTOR and Raf/MEK/MAPK), thereby triggering cell proliferation and migration. In many cell types, the activation of the IGF-1 receptor correlates with tumour progression and poor prognosis [9] . On the other hand, an accumulation of βcatenin, detected by immunohistochemical staining, occurs in more than 50% of adrenocortical adenomas (ACAs) and ACCs, and is also associated with decreased overall survival [5, 9] . Further pathways potentially involved in the pathogenesis of ACC include changes in notch signalling and alterations in adrenocortical microRNA profiles [5] . Decreased miR-195 and increased miR-483-5p levels have been observed in ACC patients with the worst prognoses [9] .
In this paper, we did not aim to summarise all the details of molecular alterations seen in ACC, as this has already been addressed in several reviews [5, 9] .
Clinical classification
In 2003 and 2004, the Union for International Cancer Control (UICC) proposed the TNM classification for ACC, which subsequently was revised by the European Network for the Study of Adrenal Tumours (ENSAT). Since the ENSAT classification better reflects patient prognosis, it is recommended for future clinical and research purposes [12] .
Staging
According to the ENSAT classification, stages I and II include non-infiltrating tumours ≤ 5cm and > 5 cm, respectively, without the simultaneous presence of positive lymph nodes or distant metastases. Stage III is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or venous tumour thrombus. Stage IV involves tumours with distant metastases [12] .
Clinical presentation
Symptoms ACC is a rare malignant endocrine tumour. Most adrenocortical cancers present as large masses. For those patients, symptoms are mostly related to mass effect and compression of surrounding tissues. The initial symptoms usually are weight loss, nausea, abdominal distension, back pain and other symptoms connected to distant metastases -most common to the lungs (45%), liver (42%) and lymph nodes (24%) [13] .
Although 60-70% of ACCs are biochemically found to overproduce hormones, it is not clinically apparent in many cases. This may be due to relatively inefficient steroid production in ACC, manifesting with increased steroid precursors, due to a de-differentiated and thus incomplete pattern of steroidogenic enzyme expression. However, if these hormones are biochemically active, patients can present with endocrine symptoms including signs of hypercortisolaemia, virilisation or gynaecomastia (Table I) . In adults, 30-40% of patients manifest a clinical picture of Cushing's syndrome (CS) with classic signs including buffalo hump, moon facies, osteoporosis, hypertension, and newly diagnosed diabetes, while 20-30% manifest syndromes of virilisation with associated hirsutism and oligomenorrhea
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or altered libido [14] . In men, oestrogen overproduction related to ACC may result in gynaecomastia or low libido [15] . Some cases can also present with a rare but serious paraneoplastic syndrome including thromboembolic disease or non-islet cell tumour hypoglycaemia (NICTH) [16] .
Childhood ACTs occur predominantly in females and almost always cause clinical signs. The most common presenting sign is virilisation (84.2%), whereas CS without virilisation remains uncommon (5.5%) [17, 18] .
Workup and diagnosis

Laboratory tests
Current biochemical work-up for adrenal masses includes extensive assessment of plasma and urinary hormones, as well as assessments of hormonal rhythm during the day and its responsiveness to inhibition (Table II) . Initial work-up include plasma hormones, which potentially may serve later as a biochemical marker of ACC recurrence in a particular patient. Differentiation between adrenal cortex and medulla lesion is based on biochemistry (urinary and plasma catecholamines and metanephrines) and imaging (CT and MIBG scans).
Urinary steroid profiling (USP) has been reported to be a good discriminator between ACC and other adrenal lesions. It also may indicate adrenocortical insufficiency after a surgical procedure and serve in the follow up and monitoring of the recurrent disease [14] . Currently, USP is available is several centres (e.g. King's College London, UK) and the only limitation of its use is related to its high price. In King's College Hospital, USP is routinely used in pre-surgical diagnostic work-up. If USP normalises after radical tumour removal, it can subsequently serve as a tool in the early detection of recurrence of disease if the specific markers for a particular patient recurred. Interestingly, even though mitotane influences USP pattern, it still can be used for early detection of the recurrence of disease [19] .
Pathology
The pathology report should demonstrate the adrenocortical origin of the lesion (e.g. by steroidogenic factor 1 staining) and provide Weiss score, resection status, and quantitation of the proliferation marker Ki-67 to guide further treatment. Two large ENSAT studies have demonstrated that the quantification of the proliferation marker Ki-67 is highly important because Ki-67 is the most powerful prognostic marker in both localised and advanced ACC [5] . The Weiss system, which is currently the most popular, combines nine morphological parameters, of which three are structural ('dark' cytoplasm, diffuse architecture, necrosis), three are cytological (atypia, mitotic count, atypical mitotic figures), and three [20, 21] . High mitotic rate, high nuclear grade, atypical mitoses, capsular or vascular invasion suggest high malignancy. There is also the McFarland Scale; standards 1 and 2 have better chances of survival than 3 and 4 which include distant metastases [22] .
Immunochistochemistry
Some studies have indicated the role of Ki-67 in differentiating between benign and malignant adrenal tumours.
A significantly higher expression of Ki-67 (> 10%) positively correlates with a worse prognosis. Moreover, it has a high diagnostic accuracy. The loss of the suppressive function by the p53 gene is the common molecular reason for malignant carcinoma in humans. Other studies have found that there is a statistically significant correlation between the expression of p53, p21, Ki-67 and the differential diagnosis of adrenocortical adenoma and adrenal cortical carcinoma [7] . The best results were obtained with a combination of IGFII and Ki-67, with 96% sensitivity and 100% specificity in diagnosing ACC [21] .
Imaging
Current imaging methods have greatly improved the diagnosis and staging of ACC. Imaging studies of choice are CT and MRI, the role of which in distinguishing adrenocortical adenoma and adrenocortical cancer is increasing; also recently more often FDG-PET (positron emission tomography with use of 18-fluorodeoxyglucose) which is useful in differentiating between benign and malignant adrenal lesions. CT and MRI are equally sensitive. Non-contrast enhanced CT is primary a modality for the diagnosis of adrenal lesions. It allows the detection of 95% of adrenal masses, and the characterisation of most of them [23] . Still, the size of adrenal mass estimated in CT or MRI is the most specific indicator of tumour malignancy. A tumour size of between 5cm and 6cm is diagnostically challenging. CT allows a precise assessment of features such as tumour size, shape, homogeneity and calcifications. The tumour size corresponds with the risk of malignancy [23] . Dynamic MRI is reported to give contributory information to findings. Also 3-T MRI volumetric imaging is expected to improve the sensitivity and specificity for the diagnosis of lipid-poor adenomas [24] . Using these diagnostic methods, it is possible to discover huge lipid-poor heterogeneous lesions [25] [26] [27] . ACC usually occurs as a unilateral tumour of size 5-6 cm (median tumour size at diagnosis -about 10cm), often compressing the kidney. Regardless of tumour size, heterogeneity with necrosis, lack of clear margins, low content of lipid tissue, high density, pseudocysts, and calcifications appears to collate with malignancy [26, 27] . Moreover, for lesions with > 10 HU on unenhanced CT or a delayed washout of > 50% with a delayed attenuation of 35 HU, ACC should be suspected [4, 13, 23, 26] . Bone scintigraphy is very useful in diagnosing bone metastases, although it can give false positive results in patients with CS, because of remodelling of bone tissue and possible fractures. The latest research shows that the use of 18-FDG-PET can help in differentiating between benign and malignant adrenal lesions [28] . Furthermore, there are some studies concerning the use of 11C-metomidate in revealing ACC and ACA [26, 28] . In a case of a positive scan with tumour SUV max > 10, ACC should be suspected [24] .
Other diagnostic tools
FNAB (fine needle aspiration biopsy)
This is not recommended, except for possible metastases [29] especially, because of the significant risk of neoplastic spread [30, 31] . It is also said that biopsy can result in complications that could increase the difficulty of operation, or, in a case of malignant lesion, seed tumour cells. The indications for percutaneous adrenal biopsy are suspected infection or adrenal metastasis [32] . According to Fassnacht et al., the only two scenarios with potential benefit comprise: 1) those few patients with metastatic disease not scheduled for surgery, in which other methods have failed to establish the diagnosis; and 2) patients with a suspicious endocrine-inactive adrenal mass and history of extra-adrenal malignancy [5] . If there is a need for biopsy, it is very important to exclude pheochromocytoma prior to the test to avoid the development of catecholaminergic crisis [33] .
Prognostic markers
In general, in adults, cortisol production, tumour stage and tumour grade have been identified as negative prognostic factors in ACC with regards to overall survival and recurrence of disease [34] . A major limitation of that study (as the authors mentioned themselves) was that only symptomatic patients were considered as having hypercortisolism, thus excluding information on the prognostic role of elevated cortisol levels in the absence of a clinical syndrome. In summary, clinically relevant hypercortisolism has now been shown to be a new prognostic factor in patients with completely resected ACC receiving adjuvant mitotane. Interestingly, the efficacy of adjuvant mitotane does not seem to be influenced by overt hypercortisolism [35] .
The International Paediatric Adrenocortical Tumour Registry, based on a multivariate analysis, reported that disease stage, presenting signs of endocrine dysfunction, and age were independently associated with prognosis in adrenocortical tumours diagnosed in childhood [36] .
Management
Because of ACC's rarity, and also the limited clinical series, there are only a few treatment strategies. Current practice is influenced by expert consensus opinion which is gathered from medical centres that specialise in ACC. The evaluation of the best treatment methods and studies gathering more comprehensive evidence are still ongoing. The ongoing international efforts, including comprehensive '-omic approaches' and nextgeneration sequencing, will improve our understanding of the pathogenesis and hopefully lead to better therapies [5] . Whenever possible, patients should be treated within clinical trials: (www.clinicaltrials.gov).
Surgical menagement
Surgery still remains the treatment of choice for many cancers, including ACC. Stages I and II have the best survival rates when treated surgically [1] . The aim is to achieve a complete resection (R0) as well as en bloc resection of invaded tissues and lymph nodes [26, 37] . Even after R0 resection, recurrence of the disease is frequent in about 85% [27, 37] .
Five-year survival for all ACC stages is as follows: I -60%, II -58%, III -24%, and IV -0% [38] . An experienced surgical team that provide R0 resection with accurate margins gives the best result for patients from stages I-III. Although there is no consensus about what qualifies an expert ACC surgeon, it is proposed that surgery for suspected ACC should be limited to surgeons with > 20 adrenalectomies per year [5] . The use of laparotomy and laparoscopic methods is still being discussed. Although in a case of noninvasive tumour < 10 cm the laparoscopic method could be as effective as open surgery, open adrenalectomy via a flank or the thoracoabdominal approach remains the standard [27, 37, 39] . In some centres, patients with open adrenalectomy had improved overall survival [32] . Even if radical surgery was performed, the majority will develop metastases within 6-24 months [28] .
All patients considered at high risk of recurrence should receive mitotane as the treatment of choice, and also those not amenable to surgery as adjuvant therapy [27, 39, 40, 41] . According to the German Adrenocortical Carcinoma Registry, it is estimated that in stages I and II R0, and with Ki-67 < 10%, mitotane therapy is recommended [27, 39] . Other studies show that surgery with immediate adjuvant long term therapy was the most effective form of therapy for patients with ACC [42] . In patients with a high risk of recurrence (e.g. R1-incomplete microscopic tumour removal), radiotherapy to the tumour bed should be performed [43] . Even though mitotane therapy has increased recurrence-free survival, with a further improvement achieved by adjuvant radiation therapy, still this combined treatment does not eventually impact upon overall survival and remains controversial [34] .
Due to the fact that the risk of recurrent disease is high, follow up visits should continue for a minimum of five years [6] . As ACC is often diagnosed at an advanced stage, a sudden retroperitoneal haemorrhage, which is a life-threatening event, may be the first symptom of the disease. A clinical analysis suggests that retroperitoneal haemorrhage is a poor prognostic factor [44] . The diagnosis of such a haemorrhage can be made on the basis of 3D (three-dimensional) sonography. What is more, a 3D power Doppler sonography is better than 2D in the visualisation and identification of vessels supplying the tumour [45] .
Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane], isomer of the pesticide DDD, directly toxic to adrenocortical cells
Mitotane remains the main chemotherapeutic agent in ACC treatment. It has been used for 50 years in the treatment of adrenocortical carcinoma [26] . It is given orally in 500 mg tablets (Lysodren; HRA Pharma Paris, Bristol-Myers Squibb). Due to its high specificity towards adrenocortical cancer cells, it is used as a treatment of choice in patients with distant metastases, as
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adjuvant therapy, and also in cases of recurrent disease [27, 40, 41] . Kasperlik-Załuska, in a review of 40 years of mitotane in the treatment of ACC, showed that mitotane administered immediately after surgery appears to be more efficient than when administered later. Furthermore, it is used with good results in the treatment of CS of non-malignant origin for patients with poor tolerance for adrenal inhibitors [42] . Mitotane has a specific cytotoxic effect on mitochondria of adrenal cortical cells. It has been reported to inhibit cortisol biosynthesis in vitro and enhance production form exogenous cortisol of urinary 6β-hydroxycortisol and unidentified polar unconjugated metabolites [46] .
In a recent pre-clinical study, it has also been reported that mitotane reduced the viability of NCIH295R cells (human ACC cell line) through the induction of apoptosis triggered by increased caspase-3 and 7 activities. This study indicated that mitotane markedly inhibited the expression of genes involved in steroidogenesis, secretion of cortisol, and DHEAS [47] . In humans, the exact mechanism of its action remains to be fully elucidated. Mitotane alters steroid peripheral metabolism and directly suppresses the adrenal cortex. It inhibits pregnenolone and cortisol synthesis.
It inhibits the cholesterol side chain cleavage and 11-β-hydroxylation reactions. It induces CYP3A4 and inhibits 5 alpha-reductase, which causes inactivation of more than 50% of supplemented hydrocortisone during the therapy [41] . The induction of CYP3A4 has a major impact on the care of ACC patients by lowering the blood levels of many drugs frequently co-administered with mitotane [5] . Mitotane apparently causes adrenal inhibition without cellular destruction. Ghataore et al. concluded that mitotane causes consistent changes in cortisol metabolism, most of which have not been previously recognised. Induction of 6β-hydroxylation offers an explanation for a reported decrease in cortisol bioavailability. Mitotane also has potential as a unique steroid metabolic probe for 20β-reduction [46] .
When to use mitotane?
In cases of non-operative ACC (active and nonfunctioning tumours), it controls hormonal excess in about 70-75% of patients. Monitoring the drug level (therapeutic levels of 14-20 mg/L) is highly important, because a good response to the treatment depends heavily on the drug serum levels [48, 49] . In a long term study of patients with regional and metastatic ACC, scientists showed that the levels of o,p'-DDE (mitotane metabolite) were more closely related to clinical improvement or remission than o,p'-DDD levels (1,1-(dichlorophenyl)-2,2-dichloroethane; mitotane) [42] . About 40% of the drug is absorbed and approximately 10% of the dose is recovered in the urine as water-soluble metabolite. Plasma terminal half-life varies from 18 to 159 days, mainly due to its accumulation in adipose tissue and it is detected in blood even several months after the patient has ceased to take it [26] . It is recommended to increase the dose until an adverse reaction interferes in cases of improved clinical response and tolerance [50] . Possible side effects of mitotane therapy include: increase in aminotransferase and alkaline phosphatase activity, fall in the number of leukocytes, platelets and erythrocytes, and myasthenia in a few cases [42] . Furthermore, all patients develop adrenal insufficiency, which has to be replaced with a high dosage of hydrocortisone [5] .
The 
Combination therapy
In advanced ACC, mitotane is still the standard of care. Based on the FIRM-ACT trial, mitotane plus etoposide, doxorubicin, and cisplatin is now the established firstline cytotoxic therapy. However, most patients will experience progress and require salvage therapies [51] . It is possible to use combination therapies with cisplatin in cases which mitotane is ineffective, e.g. docetaxel and cisplatin [52] . Studies are in progress to investigate and hopefully may lead to new treatment options. Currently, only four intervention trials are recruiting patients (NCT01832974, NCT01048892, NCT00777244, and NCT01898715) [5] .
Radiotherapy
Some experts recommend radiotherapy as a palliative treatment, especially in advanced stages with symptomatic bone metastases. Meta-analysis suggests that radiotherapy should be performed to the tumour bed in patients with a high risk of local recurrence [53] . Until better evidence is available, scientists recommend a total dose > 40 Gy (grays) with single fractions of 1.8-2 Gy, even 4 Gy in some cases (including a boost volume of 50-60 Gy) [43, 54] . There are a few findings that suggest the potential benefit of palliative treatment of brain metastases or vena cava obstruction [54] . However, the role of radiotherapy remains controversial and is still discussed, especially in recurrent disease [52, 53, 54] .
Management of endocrine syndromes
It is important to treat endocrine syndromes as they significantly impact upon the patient's quality of life and well-being. In most cases, the management
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includes treatment of CS. Metyrapone, ketoconazole, and etomidate remain the most effective. Cabergoline, pasireotide, and mifepristone are rarely used due to their low efficacy [55] .
Targeted therapy
Poor understanding of the molecular alterations in tumour development is the cause of preclinical investigations and clinical trials to seek a target therapy of ACC. Many of the investigations concern tyrosine kinase inhibitors and antiangiogenic compounds.
As previously mentioned, the activation of IGF pathway takes place in ACC. Based on this knowledge, several preclinical studies involving IGF-IR inhibition have been initiated. A study concerning the IGF1R antagonist NVP-AEW541 showed a significant dose-dependent inhibition of ACC growth [56] . Another study by Doghman et al. concerning β-catenin antagonists (PKF115-584), still at a preliminary preclinical stage, showed that antagonist inhibited the transcription and proliferation of ACC cell line [57] .
Target therapy aimed at growth factors is supposed to inhibit increased angiogenesis, cell migration and proliferation. Bevacizumab is a monoclonal humanised antibody binding to VEGF. Wortmann et al., in a study of ten patients with advanced ACC, reported no response to a combination of bevacizumab with capecitabine. The therapy is not recommended. There was also a minor response for patients with advanced ACC for therapy: EGFR inhibitor erlotinib plus gemcitabine [58] . There are still investigations concerning another EGFR and IGF1R inhibitors ongoing.
Follow up
According to ENSAT, CT or MRI are recommended every 2-3 months depending on the treatment. According to Fassnacht et al., after the first two years of follow up, they gradually increase imaging intervals. However, in patients without evidence of disease, follow up for a minimum of ten years after surgery is recommended [5] . The usefulness of USP in structured follow-up after surgery is currently being assessed by the ENSAT group under Prof. W. Arlt at Birmingham.
Conclusion
ACC is a rare (0.5-2: 1 million) and malignant tumour with unclear pathogenesis and a poor prognosis. The five-year survival rate does not exceed 30% of patients. This should be borne in mind in a case of excessive secretion of adrenal hormones and an adrenal gland tumour. Literature on the subject points towards surgery as the treatment of choice. In addition, the use of chemotherapy (mitotane) gives the best results immediately after surgery. Early detection of changes in the early stage gives the best chance of total resection, and therefore the greatest chances of survival of the patient.
Therefore, it is necessary to combine a number of diagnostic methods such as diagnostic imaging, laboratory diagnostics and molecular tests, to achieve the earliest possible diagnosis and treatment.
Our own experience
Patients with ACTs represent about 10% of our patient cohort seen in our Department. Every year, we see nearly 120 adrenal lesions: 97.5% benign vs. 2.5% malignant, 15% hormonally active. More than 90% of our cases are incidentalomas. Our ACC series includes more than 40 cases in total. In our hands, the diagnosis and treatment of ACC happens within a multi-disciplinary environment, working alongside biochemists, radiologists, surgeons, pathologists, oncologists and palliative care specialists.
We have developed a strong research interest in adrenal pathology and currently run a research programme (supported by the Foundation for Polish Science and the 7 th Framework Programme of the European Union) related to pre-clinical assessment of targeted therapies in ACC in collaboration with King's College London, Barts and the London, QMUL and OCEDEM.
We selected three cases from our ACC cohort to underline some challenges that clinicians can face when dealing with malignant adrenal tumours. In the first case, we wanted to show a rapid progression of disease despite de-bulking surgical intervention, use of mitotane and chemotherapy. We presented also a rare para-neoplastic syndrome of IGF-2 mediated non-islet cell tumour hypoglycaemia (NICTH), which can develop in ACC.
The second case showed the usefulness of plasma steroids in the detection and follow up of ACC and also possible success of combined therapy with surgery, mitotane and radiotherapy, even in a case of R1 resection of the primary lesion. Interestingly, our second patient was diagnosed at the age of 27 with a negative family history of ACC. Further genetic testing might be considered, not only for research, but also for genetic counselling purposes in this case.
The third case underlines that even though the tumour was excised radically, the local and distant spread of disease occurred during mitotane adjuvant therapy. Further oncological interventions (chemotherapy and radiotherapy) slowed down disease progression; however, thrombo-embolic complications confirmed disease
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activity. In such a case, one might wonder whether a targeted therapy might be an option as a next step, and also if genetic tests are required.
Case 1
In July 2005, a 59-year-old female patient was admitted to our clinic. She presented with Cushing's syndrome and simultaneous pulmonary metastases. Patient stated that her symptoms had started six months before she presented to us and included: hypertension, weight gain with central obesity, plethora, purple striae and hirsutism. She suffered also from shortness of breath which became more apparent on exertion shortly before admission to our institution. Initially, the patient was hospitalised at the Department of Pneumonology, where a routine chest X-ray (followed by chest CT) showed disseminated interstitial lesions consistent with metastatic disease. Due to adrenal tumour which was visualised by ultrasound, the patient was transferred to our Department.
On the day of admission to our ward, the patient was in critical condition. Abdominal CT and magnetic resonance imaging (MRI) were performed and showed a 85 x 70 x 110 mm heterogenous, lobulated, enhancing mass lesion with areas of necrosis and pathological vessels at the right adrenal gland. The tumour was attached to the inferior vena cava with suspicion of local invasion. There was no evidence of abdominal lymph nodes invasion (Fig. 1) .
The blood and urine evaluation confirmed Cushing's syndrome (elevated early morning serum cortisol levels, lack of 24h cortisol rhythm, lack of cortisol suppression during overnight dexamethasone suppression test, high level of steroids in serum and in 24-hours urine samples) (Table III) . 
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After hormonal preparation (aminogluthetymide 250 mg, four times a day, one tablet, for two weeks), control of hypercortisolaemia was achieved and the patient was referred for right adrenalectomy through the open laparotomy. Complete resection of the tumour was not possible due to the fact that the mass was attached to the inferior vena cava. Even though metastatic disease and potential invasion of vena cava were confirmed on imaging prior to surgery, the decision about surgery was based on willingness to de-bulk the tumour and control its hormonal production. Microscopic examination confirmed ACC with Ki-67 at 25% (T4N1M1). Therapy with mitotane was started (9 g/24 h) along with substitution of hydrocortisone and prednisone (40 mg and 10 mg) .
In November 2005, despite the mitotane treatment and the following termo-ablation of the liver metastases, her disease progressed further (a local progression with infiltration of inferior vena cava with associated disseminated thrombosis from renal vessels to right atrium and remarkable tumour re-growth size to 140 × 110 × 70 mm). New metastatic lesions were found in the liver. Despite the fact that the steroidogenesis inhibitors were used in treatment (mitotane and aminogluthetimide simultaneously), symptoms of hypercortisolaemia along with myopathy and dyspnoea were still present.
In July 2006, the patient demonstrated symptoms of hypoglycaemia with serum glucose level below 29 mg%, decreased levels of C-peptide and insulin, and high secretion of IGF2. A diagnosis was made of IGF-2 mediated non-islet cell tumour hypoglycaemia (NICTH). Based on clear progression of disease, a decision was made to proceed with chemotherapy and the patient received five cycles of: cisplatin (50mg for three days) with etoposide (170mg for one day). Reduction of steroids and normalisation of glucose levels as well as normokalaemia were achieved.
In November 2006, in spite of chemotherapy, further progression was observed in consecutive imaging. Right hemiplegia, aphasia and coma led to the patient's death that month.
Case 2
A 27-year-old mother of a four-month-old child was hospitalised in our Department in 2011. On admission, the patient was still breast feeding. Before and after pregnancy, her blood pressure and weight were normal and her periods were regular. The patient had suffered left flank pain since the fourth month of pregnancy. She did not have any features of virilisation or hypercortisolaemia on the day of admission. Abdominal ultrasound and subsequent CT showed a right adrenal gland tumour measuring 107 × 94 × 115 mm with heterogenous contrast enhancement (from 20-40 HU to 30-70 HU). Tumour impressed the left kidney, adhered to the spleen and caudal part of pancreas. There was no evidence of abdominal lymph nodes invasion (Fig. 2) .
The blood test evaluation revealed slightly elevated adrostendione, 17-OH progesterone and partial suppression of overnight dexamethasone suppression test (Table III) . Due to the fact that ACC was highly suspected, left adrenalectomy was performed through open laparotomy. A 10 cm tumour was removed. Histopathological examination confirmed ACC diagnosis with Ki-67 index at 15% (T4NxMx). Due to the fact that the histopathological examination revealed infiltration of adrenal capsule, nearby tissues and vessels, the decision of radiotherapy to the tumour bed was made and the patient received a total dose of 54Gy (in 27 fractions). Immediately after surgery, mitotane was administered (2.5 g/24 h, under the control of serum level), along with substitution of hydrocortisone.
The surgery, followed by radiotherapy and administration of mitotane, resulted in normalisation of ACC diagnostic markers specific for this patient including androstendione (0.5 ng/mL) as well as 17-OH progesterone (1.3 ng/mL). The follow up imaging (CT, MRI) performed every six months showed no evidence of recurrent disease still today. She has remained under our follow-up for the last three years. Her biochemical indicators of ACC (which normalised after complete treatment) are checked every three months and remain negative. A family history of ACC is negative.
Case 3
A 27-year-old female was referred to our clinic in May 2009 due to the presence of left adrenal gland tumour. In her previous medical history, it was known that three years previously she suffered from extensive 
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pulmonary embolism following cholecystectomy. Two months before admission, abdominal ultrasound and computed tomography was performed due to complaints about abdominal pain. This showed a 59 mm left adrenal gland tumour with regular borders, compressing nearby organs, with a mean density of 27-33 HU and heterogeneous enhancement of 53-120 HU.
On admission, features of hypercortisolaemia were present including 'moon' facies, buffalo hump, central obesity and hirsutism. Hormonal studies revealed increased 24-hour free cortisol levels and elevation of urinary excretion 17-ketosteroids. Additionally, lack of circadian rhythm of cortisol secretion, low ACTH plasma levels and non-suppressible overnight dexamethasone test were established (Table III) . Based on these findings, ACTH-independent Cushing's syndrome was diagnosed and the decision was made on surgical intervention.
Complete left adrenalectomy was performed two weeks later, in June 2009. Histopathological findings concerning areas of tumour necrosis along with high mitotic rate (8/50) as well as proliferation index (Ki-67 at 20%) confirmed an adrenocortical cancer diagnosis. Mitotane-based chemotherapy was administered with the aim of serum level control. Moreover, hydrocortisone and prednisolone were added to the treatment, and regression of hypercortisolism symptoms was observed. Meanwhile, the patient was followed up regularly.
Unfortunately, six months after surgery a local recurrence and liver metastases were found (Fig. 3) .
There was no clinical sign of hypercortisolism. The patient was re-operated three times after the first surgery; the following were resected: a tumour that recurred locally, liver segments 2 and 3, the spleen, caudal part of the pancreas, part of the left diaphragm, and a left kidney tumour. In all histopathological samples, disease recurrence was confirmed. The patient received four cycles of chemotherapy including streptozocin and 5-FU along with mitotane.
In spite of treatment, tumour progression was observed. The patient suffered from subsequent pulmonary embolism and DVT of the right lower limb. In further imaging, there was evidence of lung and mediastinal metastases. Therefore, the patient received mediastinal radiotherapy (20 Gy in five fractions) and another chemotherapy scheme including eight cycles of: doxorubicin, etopozide, and cisplatin during the following eight months. In follow up imaging (CT), a considerable regression was observed (PFS was about five months.). The next CT showed the progression of lung metastases. Due to that fact, another chemotherapy scheme was administered: cisplatin and etopozide. Unfortunately, after the third cycle, another pulmonary embolism occurred. In echocardiography, right heart overload, general hypokinesis with EF of 30% was stated, which was the reason for chemotherapy discontinuation.
Currently, the patient is in a good condition, and regularly followed up. Mitotane is administered under serum level control. Moreover, the patient receives hydrocortisone, prednisolone and fludrocortisone as well as anticoagulant therapy. Further oncological therapy is considered after control echocardiography. 
Polish version
Wstęp
Rak kory nadnercza (ACC, adrenocortical cancer) jest nowotworem złośliwym występującym z częstością 0,5-2 przypadków na milion rocznie [1, 2] . Częściej występuje u kobiet niż u mężczyzn (wskaźnik zachorowań kobiet w stosunku do mężczyzn wynosi około 2,5-3:1) [3] .
Guzy czynne hormonalnie występują częściej u kobiet niż u mężczyzn. Wyróżnia się dwa szczyty zachorowań: w pierwszej oraz piątej dekadzie życia [1, 2, 4] . W ciągu dwóch ostatnich dekad dokonał się znaczący postęp w rozumieniu biologii molekularnej ACC, jakkolwiek nadal ma to niewielki wpływ na przeżycie pacjentów. Wydaje się, że najczęstsze zaburzenia w ACC dotyczą dwóch PRACE POGLĄDOWE szklaków sygnałowych: szlaku WNt/β kateniny oraz szlaku IGF-2. Jednakże dotychczasowe dane wskazują, że prawdopodobnie zaburzenia te nie są wystarczające do powstania transformacji nowotworowej. Jednak główne czynniki odpowiedzialne za patogenezę ACC nadal pozostają nieznane [5] . Rzadkość występowania choroby podziałała stymulująco na rozwój w kierunku wynalezienia nowych metod terapeutycznych. Niezwykle potrzebne są nowe koncepcje leczenia ACC. Obecnie wysiłek wielu grup ma charakter międzynarodowy i skierowany jest na rozszerzenie genomiki oraz sekwencjonowania nowej generacji. Miejmy nadzieję, że doprowadzi to do lepszego zrozumienia patogenezy ACC i tym samym do stworzenia lepszych opcji terapeutycznych [5] .
prezentuje objawy w postaci wirylizacji z towarzyszą-cym hirsutyzmem, zaburzeniami cyklu miesięcznego, czy zaburzeniami libido [14] . U mężczyzn nadprodukcja estrogenów może prowadzić do rozwoju ginekomastii lub obniżenia libido [15] . W niektórych rzadkich przypadkach, grożących ciężkimi powikłaniami może dojść do rozwoju choroby zakrzepowo-zatorowej bądź też hipoglikemii niezwiązanej z występowaniem guza insulinowego (NICTH) [16] .
Guzy nadnerczy u dzieci przeważają u dziewczynek i często towarzyszą im objawy kliniczne, wśród których najczęstszym objawem jest wirylizacja (84,2%). Z kolei zespół Cushinga bez cech wirylizacji u dzieci występuje niezwykle rzadko (5,5%) [17, 18] .
Diagnostyka
Badania laboratoryjne
W obecnej chwili diagnostyka biochemiczna guzów nadnerczy obejmuje badanie stężenia hormonów steroidowych w osoczu i w moczu, a także ocenę dobowego rytmu i możliwości zahamowania ich wydzielania (tab. II).
Wstępna diagnostyka dotyczy oceny stężenia hormonów w osoczu, co potencjalnie może służyć również jako marker biochemiczny nawrotu ACC w poszczegól-nych grupach pacjentów. Do różnicowania zmian kory i rdzenia nadnerczy stosuje się zarówno badania biochemiczne (osoczowe stężenia katecholamin i metanefryn), jak i diagnostykę obrazową (CT oraz scyntygrafię). Określanie profilu steroidów w moczu (USP, urinary steroid profiling) jest bardzo skuteczną metodą różnicującą ACC od pozostałych zmian w nadnerczach. Profilu steroidów w moczu może również służyć do diagnostyki niewydolności kory nadnerczy po zabiegu chirurgicznym oraz monitorowania nawrotu choroby [14] . Dostępność do badań USP w zaledwie kilku ośrodkach na świecie (np. Kings College London w Wielkiej Brytanii) jest związana jedynie z wysoką ceną badania. W Kings College Hospital USP jest stosowane rutynowo w diagnostyce przed zabiegiem operacyjnym. Jeśli wyniki USP normalizują się tuż po zabiegu radykalnego usunięcia guza, metoda ta może posłużyć jako narzędzie diagnostyczne we wczesnym wykrywaniu wznowy choroby nowotworowej. Interesujące jest to, że mimo wpływu mitotanu na test USP, nadal może on być wykorzystywany do wczesnego wykrywania nawrotu choroby [19] .
Histopatologia
Wynik badania histopatologicznego powinien zawierać informacje potwierdzające pochodzenie zmiany z tkanki kory nadnerczy (np. w barwieniu SF1), dostar- Monitorowanie pacjenta "follow-up"
-CT or MRI jamy brzusznej oraz CT klatki piersiowej, co 2-3 miesiące (w zależności od zastosowanej metody leczenia)
